Dave Sheehan has joined ContextMedia:Health as chief marketing officer.
Grey Doyle is appointed CEO of Leading BioSciences Inc. Doyle, a long-standing member of Leading BioSciences’ executive management team and board of directors, previously served as chief operations officer and chief financial officer.
Glenn Nedwin, Ph.D., has become CEO, president, and member of the board of directors of Second Genome Inc.
The latest innovation in oncology research is tying tumor biomarkers to specific treatments in order to improve patient outcomes. Med Ad News spoke with Gerald Messerschmidt, M.D., chief medical officer of Precision Oncology, to find out how the biomarker-treatment link will help get treatments to market, and to the right patients, faster.
Scheduled for September 23, 2016 in Washington, DC, USA Princeton, NJ—August 15, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced that it is holding a Stakeholder Conference […]
Though the cost of CRM systems varies widely, life sciences companies in particular pay a high price for SaaS software subscription fees – often double or more than what other industries pay.
Leadership today equals leading, managing and constantly adapting to change. Here are some steps to get on a path to change and engage your organization.
Almost every reported concomitant medication has a reason – and many, if not all of these reasons should be reported as adverse events.
Virtus Pharmaceuticals Inc. – a specialty niche pharmaceutical company and part of the Linden Capital Partners portfolio – announced it launched Prometrium (Progesterone, USP Capsules), the company’s first branded product.
